+3
Loading...
Alpha-2 antiplasmin (α2AP) is a key serine protease inhibitor found in plasma at approximately 70 μg/mL, primarily synthesized by the liver. Its main function is to regulate fibrinolysis by rapidly and efficiently inhibiting plasmin, the enzyme responsible for breaking down fibrin clots. By binding to plasmin and preventing its activity, α2AP stabilizes blood clots and prevents excessive bleeding. It also interferes with plasminogen binding to fibrin and becomes cross-linked to fibrin during clot formation, further enhancing clot stability.
Deficiency of α2AP is a rare inherited coagulation disorder that results in unrestrained plasmin activity and excessive fibrinolysis, leading to a significant risk of spontaneous or postoperative bleeding. This condition may present as severe bleeding episodes, particularly after trauma or surgery. Therapeutically, antifibrinolytic agents such as aminocaproic acid or tranexamic acid are commonly administered to patients with α2AP deficiency to prevent or control bleeding, especially in surgical settings.
Beyond bleeding disorders, elevated α2AP levels are linked to increased risk and poor outcomes in cardiovascular diseases, including deep vein thrombosis and ischemic stroke, making it a potential therapeutic target in these conditions.
Common uses include coagulation/fibrinolytic studies, Proteolytic enzyme studies, assay standards, IVD standards, calibrators and controls.
Not a hazardous substance or mixture.
11 - Combustible Solids
